Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Determine the Effect of Switching to Aripiprazole Once Monthly for Subjects With Schizophrenia Experiencing Worsening Sexual Dysfunction With Invega Sustenna or Risperdal Consta

NCT02472652 is registered in ClinicalTrials.gov with Gazda, Thomas D., M.D., PC as lead sponsor.

NCT NCT02472652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02472652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Determine the Effect of Switching to Aripiprazole Once Monthly for Subjects With Schizophrenia Experiencing Worsening Sexual Dysfunction With Invega Sustenna or Risperdal Consta
Lead sponsor
Gazda, Thomas D., M.D., PC
Phase
Phase 4
Overall status
Terminated
Start date
June 30, 2015
Completion date
March 1, 2017
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sexual dysfunction